The Asia Pacific Pregnancy Testing Market size is expected to grow USD 0.31 Billion by 2026 from USD 0.23 Billion in 2021, growing at a CAGR of 6.09% between 2021 to 2026.
Pregnancy tests are tests used to detect reproductive hormones such as Follicle Stimulating Hormone or Luteinising Hormone. Fertility rapid test kits help determine the exact day of ovulation or confirm the presence of menopause in women, whereas they are used to detect the sperm count.
Asia-Pacific Pregnancy and fertility devices market is driven by key factors such as rising demand for fast and self-contained tests, growing prevalence of infertility and gynecological disorders, accessibility of decentralized diagnostic tests over time-consuming laboratory tests. Escalating first-time pregnancy age and technological advancements are some of the factors supporting the growth of the market.
However, the low adaptation rate to these kits and high price are factors restraining the growth of the market.
This research report on the Asia Pacific Pregnancy Testing Market has been segmented and sub-segmented into the following categories:
By Product:
By Test Type:
By Distribution Channel:
By Country:
Regionally, Asia Pacific is estimated to be the fastest-growing region due to its high population base and increasing gynecological disorders. China is the largest for pregnancy testing within the Asia-Pacific region, while India is expected to be the fastest-growing segment.
Notable companies dominating the Asia-Pacific Pregnancy Testing Market are Abbott Laboratories, Cardinal Health, Church & Dwight, Germaine Laboratories, Kent Pharmaceuticals, Piramal Enterprises, Prestige Brands Holdings, Procter & Gamble Co., Quidel Corporation, and SPD Swiss Precision Diagnostics.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.1.1 Pregnancy Test Kits
5.1.1.1 Strips/Dip Sticks & Cards
5.1.1.2 Mid-Stream
5.1.1.3 Cassette
5.1.1.4 Digital Devices
5.1.2 Ovulation/Fertility Test Kits
5.1.2.1 Line Indicator Devices
5.1.2.2 Digital Devices
5.2 By Test Type
5.2.1 FSH Urine Test
5.2.2 Luteinizing Hormone (LH) Urine Test
5.2.3 Human Chorionic Gonadotropin (hCG) Hormone Blood Test
5.2.4 Human Chorionic Gonadotropin (hCG) Hormone Urine Test
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Alere Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Quidel Corporation
8.3 Prestige Brands Holdings
8.4 Church & Dwight Co
8.5 bioMérieux SA
8.6 Geratherm Medical AG
8.7 Germaine Laboratories
8.8 Abbott Laboratories
8.9 Kent Pharmaceuticals
8.10 Rite-Aid
8.11 Procter & Gamble Co.
8.12 DCC Plc.
8.13 Swiss Precision Diagnostics GmbH
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
